Maintenance Trials
1. Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT01725165 |
This study is active, but not recruiting participants.
This randomized phase II trial studies how well surgery and/or radiation therapy or standard therapy and/or clinical observation works in treating patients with previously treated stage IV non-small cell lung cancer. Radiation therapy uses high energy x-rays to kill tumor cells. Giving surgery and/or radiation therapy may be more effective than standard therapy and/or clinical observation in patients with previously treated non-small cell lung cancer.
Ontario
London Health Sciences Centre
London, Ontario, N6A 5W9
2. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
| ClinicalTrials.gov Identifier: |
NCT02486718 |
This study is active, but not recruiting participants.
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer.
Ontario
Etobicoke
East York
QC
Laval
3. A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)
| ClinicalTrials.gov Identifier: |
NCT04513925 |
This study is currently recruiting participants.
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Manitoba
CancerCare Manitoba, Winnipeg
Ontario
Royal Victoria Regional Health Centre, Barrie
William Osler Health System - Brampton Civic Hospital, Brampton
Ottawa Hospital Research Institute, Ottawa
Health Sciences North, Sudbury
Quebec
Jewish General Hospital, Montreal
4. Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
|
ClinicalTrials.gov Identifier:
|
NCT03703297
|
This study is currently recruiting participants.
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy.
Alberta
Edmonton
Manitoba
Winnipeg
Ontario
Hamilton
London
Ottawa
Toronto
Quebec
Montreal
5. Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT03793179 |
This study is currently recruiting participants.
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer.
British Columbia
BCCA-Fraser Valley Cancer Centre, Surrey
BCCA-Vancouver Cancer Centre, Vancouver
New Brunswick
Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John
Ontario
Kingston Health Sciences Centre, Kingston
Niagara Health System-Saint Catharines General, Saint Catharines
University Health Network-Princess Margaret Hospital, Toronto
Prince Edward Island
PEI Cancer Treatment Centre-Queen Elizabeth Hospital, Charlottetown
Quebec
The Research Institute of the McGill University Health Centre (MUHC), Montreal
CHA Hopital L'Enfant-Jesus, Quebec City
6. Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT03137771 |
This study is currently recruiting participants.
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact, 780-432-8500
Principal Investigator: Brock J. Debenham
Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site Public Contact, 613-761-4395
Principal Investigator: Robert M. MacRae
7. Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)
| ClinicalTrials.gov Identifier: |
NCT03833154 |
This study is currently recruiting participants.
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
Alberta
Edmonton
Ontario
London
Toronto
Quebec
Montreal
8. Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)
| ClinicalTrials.gov Identifier: |
NCT02504372 |
This study is active, but not recruiting participants.
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
Quebec
Merck Canada
Kirkland, Quebec, Canada, H9H 4M7
Contact: Medical Information Centre/Centre d'information medicale Merck Canada Inc.,
514-428-8600/1-800-567-2594
9. A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT04267237 |
This study is currently recruiting participants.
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.
Ontario
Princess Margaret Hospital, Toronto
10. Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)
| ClinicalTrials.gov Identifier: |
NCT04385368 |
This study is currently recruiting participants.
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
British Columbia
Victoria
New Brunswick
St. John
Ontario
Kingston
London
Ottawa
Sudbury
Quebec
Montreal